Lincoln Pharmaceuticals
NSE: LINCOLN · ISIN INE405C01035 · Healthcare
₹520.10+6.40 (+1.25%)
Monday 9 November, 12:40 IST. Delayed. Source: Yahoo Finance.
Price chart
₹520.10 +6.40 (+1.25%) today
The day
- Previous close
- ₹513.70
- Open
- ₹520.50
- Day high
- ₹528.65
- Day low
- ₹514.20
Listed on NSE since 17 December 2015.
Key numbers
- Market value
- ₹1,028.93 Cr
- P/E (trailing)
- 10.62
- EPS (trailing)
- ₹48.38
- Price to book
- 1.27
- Dividend yield
- 0.35%
- Return on equity
- 12.7%
- Debt to equity
- 0.00
- Profit margin
- 13.4%
- Beta
- 0.52
- Volume today
- 20,917
- Average volume
- 57,741
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹504.95 Cr | ₹72.90 Cr |
| FY24 | ₹580.55 Cr | ₹93.30 Cr |
| FY25 | ₹615.25 Cr | ₹82.35 Cr |
| FY26 | ₹662.29 Cr | ₹87.89 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q2 FY27Jul–Sep 2026 | ₹191 Cr | ₹0 | – |
| Q1 FY27Apr–Jun 2026 | ₹177 Cr | ₹0 | – |
| Q4 FY26Jan–Mar 2026Audited | ₹187 Cr | ₹0 | – |
| Q3 FY26Oct–Dec 2025 | ₹166 Cr | ₹0 | – |
| Q2 FY26Jul–Sep 2025 | ₹163 Cr | ₹0 | – |
| Q1 FY26Apr–Jun 2025 | ₹154 Cr | ₹0 | – |
Source: Lincoln Pharmaceuticals’s results filed with NSE, consolidated (the whole group). Net profit is the share of Lincoln Pharmaceuticals’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | September 2026 | March 2026 |
|---|---|---|
| Fixed assets | ₹196 Cr | ₹195 Cr |
| Investments | ₹245 Cr | ₹209 Cr |
| Inventories | ₹82 Cr | ₹80 Cr |
| Owed by customers | ₹164 Cr | ₹161 Cr |
| Cash and equivalents | ₹21 Cr | ₹22 Cr |
| Total assets | ₹964 Cr | ₹890 Cr |
| Borrowings | ₹3 Cr | ₹4 Cr |
| Total liabilities | ₹153 Cr | ₹133 Cr |
| Shareholders’ equity | ₹812 Cr | ₹758 Cr |
Source: Lincoln Pharmaceuticals’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.
About Lincoln Pharmaceuticals
Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India and internationally. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, anti-infective, anti-bacterial, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics in the form of tablets, capsules, injectables, dry syrups, sprays, ointments etc. It exports its products to Europe, Canada, Latin and North America, Africa, Asia, and South East Asia. Lincoln Pharmaceuticals Limited was incorporated in 1979 and is based in Ahmedabad, India.
- Industry
- Drug Manufacturers - Specialty & Generic
- Based in
- Ahmedabad
- Employees
- 1,352
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Lincoln Pharmaceuticals in the last day or two.
Dividends and corporate actions
All companies- Dividend - Rs 1.80 Per Share
Dividend · ex-date 11 September 2026
- Dividend - Rs 1.80 Per Share
Dividend · ex-date 12 September 2025
- Dividend - Rs 1.80 Per Share
Dividend · ex-date 13 September 2024
- Annual General Meeting/Dividend - Rs 1.50 Per Share
Dividend · ex-date 15 September 2023
- Annual General Meeting/Dividend - Rs 1.50 Per Share
Dividend · ex-date 15 September 2022
- Dividend - Rs 1.50 Per Share
Dividend · ex-date 16 September 2021
- Annual General Meeting
Action · ex-date 17 September 2020
- Interim Dividend - Rs 1.5 Per Share
Dividend · ex-date 5 March 2020 · record date 6 March 2020
Source: NSE. Latest first, 8 of 12.
Information only, not investment advice. Prices are delayed.